咨询热线:

020-3107 8154

Angiotensin II human 血管紧张素Ⅱ; Angiotensin II; Ang II; DRVYIHPF

Angiotensin II (Angiotensin II) 是一种血管收缩剂,是肾素/血管紧张素系统的主要生物活性肽。Angiotensin II human 在调节人类血压中起着核心作用,主要通过血管紧张素 II 与 G 蛋白偶联受体 (GPCRs)、血管紧张素II 1型受体 (AT1R) 和血管紧张素II 2型受体 (AT2R) 之间的相互作用来介导。Angiotensin II human 刺激交感神经刺激,增加醛固酮生物合成和肾脏活动。Angiotensin II human 诱导血管平滑肌细胞生长,增加成纤维细胞中 I 型和 III 型胶原的合成,导致血管壁和心肌增厚,并导致纤维化。Angiotensin II human 也诱导细胞凋亡 (apoptosis)。Angiotensin II human 通过 LOX-1 依赖的氧化还原敏感途径诱导内皮细胞毛细血管形成。

  • 货号:
    TK0175
  • 规格:
    1mg
    1mg
    5mg
    10mg
  • 价格:
    0.00

产品参数

CAS No.4474-91-3
生物活性Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway.
分子式C50H71N13O12
分子量1046.18
运输条件Room temperature in continental US; may vary elsewhere.
储存条件Protect from light, stored under nitrogen
溶解性数据DMSO : 220 mg/mL (380.89 mM; Need ultrasonic)
体内研究Angiotensin II human (5 mL of 1 nM; intraperitoneal injection; 200-250 g Sprague-Dawley rats) induces a significant neutrophil recruitment that was maximal at 4 hours and had resolved by 24 hours. To distinguish the AT1 receptor population that is critical for the pathogenesis of hypertension, osmotic minipumps are implanted s.c. into each animal to infuse Angiotensin II (1000 ng/kg/min) continuously for 4 weeks. Angiotensin II causes hypertension by activating AT1 receptors in the kidney promoting sodium reabsorption.
体外研究Most of the known actions of Angiotensin II (Ang II) are mediated by AT1 receptors, the AT2 receptor contributes to the regulation of blood pressure and renal function . Angiotensin II raises blood pressure (BP) by a number of actions, the most important ones being vasoconstriction, sympathetic nervous stimulation, increased aldosterone biosynthesis and renal actions. Other Angiotensin II actions include induction of growth, cell migration, and mitosis of vascular smooth muscle cells, increased synthesis of collagen type I and III in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. These actions are mediated by type 1 Ang II receptors (AT1). Angiotensin II (1 nM) induces the expression of LOX-1 and VEGF and enhances capillary formation from human coronary endothelial cells in Matrigel assay. Angiotensin II -mediated expression of LOX-1 and VEGF, capillary formation, intracellular reactive oxygen species generation, and phosphorylation of p38 as well as p44/42 mitogen-activated protein kinases, are suppressed by anti-LOX-1 antibody, nicotinamide-adenine dinucleotide phosphate oxidase inhibitor apocynin and the Ang II type 1 receptor blocker Losartan, but not by the Ang II type 2 receptor blocker PD123319.
文献•Sci Transl Med. 2021 Jul 21;13(603):eaaz4959. •Circ Res. 2020 Mar 13;126(6):e15-e29. •Acta Pharm Sin B. 21 September 2021. •JCI Insight. 2020 Jul 9;5(13):e138505. •Pharmacol Res. 2020 Dec 19;164:105391. •Oxid Med Cell Longev. 2019 Nov 23;2019:4025496. •Acta Pharmacol Sin. 2021 Jul;42(7):1090-1100. •Front Pharmacol. 24 June 2021. •Phytomedicine. 2021, 153675. •J Cell Mol Med. 2020 Apr;24(8):4748-4761. •J Cell Mol Med. 2019 Nov;23(11):7449-7461. •Int J Biochem Cell Biol. 2020 Apr;121:105703. •Cell Cycle. 2020 Oct;19(20):2734-2744. •Sci Rep. 2022 Jan 10;12(1):344. •Am J Physiol Cell Physiol. 2020 May 1;318(5):C913-C930. •Microorganisms. 2021, 9(2), 452. •Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H580-H592. •Biochem Biophys Res Commun. 2021 Apr 13;557:77-84. •Biochem Biophys Res Commun. 2021 Mar 17;552:84-90. •Microvasc Res. 2021 Dec 20;104299. •Microvasc Res. 2020 Nov;132:104043. •J Pharmacol Sci. 2019 Sep;141(1):70-78. •Bioengineered. 2022 Feb;13(2):2597-2609. •Am J Physiol Renal Physiol. 2021 Jan 11. •Exp Biol Med. 2020 Jun;245(11):983-993. •J Healthc Eng. 05 Jan 2022. •Cardiovasc Diagn Ther. 2020 Apr;10(2):107-123. •BMC Cardiovasc Disord. 2021 May 31;21(1):266. •Nephrology (Carlton). 2019 Nov;24(11):1103-1114. •Physiol Res. 2020 Nov 16;69(5):813-822. •Arch Biol Sci. 2021 Jun. •Patent. US20210277021A1. •bioRxiv. 2020 Mar.
纯度及产品资料98%